Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 902
Filtrar
1.
J Infect Dev Ctries ; 18(4): 595-599, 2024 Apr 30.
Artículo en Inglés | MEDLINE | ID: mdl-38728642

RESUMEN

INTRODUCTION: This study aims to show the bacteriologic picture of acute prostatitis and bacteremia caused by infective agent after transrectal ultrasound-guided prostate biopsy (TRUSBx) and to determine the resistance rates of the infections in patients undergoing transrectal biopsy and to guide prophylaxis approach before biopsy. METHODOLOGY: The retrospective data of 935 patients who underwent TRUSBx between January 2010 to January 2019 were reviewed. Pre-biopsy urine cultures and antimicrobial susceptibility were obtained. Subsequently, patients admitted to the hospital with any complaint after biopsy were examined for severe infection complications. RESULTS: Of the 430 (61.7%) patients who underwent urine culture before the procedure, 45 (10.5%) had growth; 30 (66.7%) of the growing microorganisms were Escherichia coli. Twenty (44.4%) of all Gram-negative agents in pre-biopsy urine culture were susceptible to quinolone. Post TRUSBx bacteremia was present in 18.2%, urinary system infection in 83.6%, and hospitalization in 61.8% of 55 patients who were admitted to the hospital. In the isolated gram-negative microorganisms, fluoroquinolones resistance in urinary system infections was seen in 40% and bacteremia was seen in 70% of the cases. ESBL-producing Gram-negative bacteria were determined in 40% of infections in blood and 38.5% of urinary system infections in the post biopsy period in the current study. CONCLUSIONS: These high antibiotic resistance rates suggest that we better review our pre-procedure prophylaxis approaches.


Asunto(s)
Antibacterianos , Profilaxis Antibiótica , Bacteriemia , Próstata , Humanos , Masculino , Estudios Retrospectivos , Profilaxis Antibiótica/métodos , Persona de Mediana Edad , Anciano , Próstata/patología , Próstata/microbiología , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Bacteriemia/prevención & control , Bacteriemia/microbiología , Farmacorresistencia Bacteriana , Prostatitis/microbiología , Prostatitis/prevención & control , Biopsia Guiada por Imagen/efectos adversos , Biopsia Guiada por Imagen/métodos , Infecciones Urinarias/prevención & control , Infecciones Urinarias/microbiología
2.
Rev Int Androl ; 22(1): 38-43, 2024 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-38735876

RESUMEN

It is estimated that microorganisms colonize 90% of the body surface. In some tracts, such as the genitourinary tract, the microbiota varies throughout life, influenced by hormonal stimulation and sexual practices. This study evaluated the semen differences and presence of Lactobacillus crispatus, Lactobacillus iners, Gardnerella vaginalis and Atopobium vaginae in semen samples from patients with symptoms of chronic prostatitis and men asymptomatic for urogenital infections. Fifty-three semen samples were included: 22 samples from men with symptoms of chronic prostatitis and 31 asymptomatic men (control group). In addition to the presence of L. crispatus, L. iners, G. vaginalis and A. vaginae, semen parameters, total antioxidant capacity of seminal plasma, prostatic antigen and some proinflammatory cytokines were evaluated in each semen sample. Volunteers with symptoms of chronic prostatitis presented a lower percentage of sperm morphology (4.3% vs. control group 6.0%, p = 0.004); in the semen samples of volunteers in the group asymptomatic for urogenital infections, microorganisms associated with the vaginal microbiota were detected more frequently. The presence of bacteria in the vaginal microbiota can also benefit male reproductive health, which undergoes various modifications related to lifestyle habits that are susceptible to modification. Microorganisms associated with the vaginal microbiota, such as L. crispatus, L. iners, G. vaginalis and A. vaginae, may have a protective role against the development of male genitourinary diseases such as prostatitis.


Asunto(s)
Coito , Microbiota , Prostatitis , Semen , Humanos , Masculino , Prostatitis/microbiología , Semen/microbiología , Adulto , Microbiota/fisiología , Gardnerella vaginalis/aislamiento & purificación , Lactobacillus/aislamiento & purificación , Vagina/microbiología , Persona de Mediana Edad , Actinobacteria/aislamiento & purificación , Femenino , Adulto Joven , Enfermedad Crónica , Estudios de Casos y Controles , Análisis de Semen , Citocinas/metabolismo , Citocinas/análisis
3.
Prostate Cancer Prostatic Dis ; 27(2): 300-304, 2024 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-38555411

RESUMEN

BACKGROUND: Even if Meares-Stamey 4-glass (M&S) test is regarded a decisive tool for diagnosing prostatitis its use is only rarely performed in everyday clinical practice. Here, we analyze if the diagnostic yield of the M&S test could be improved by a pre-test categorization of patients due to undergo a M&S test. METHODS: All clinical and microbiological data of patients who underwent M&S test in two urological centers from January 2004 to December 2021 were analyzed in this retrospective cohort study. One center has a dedicated staff member for the study of prostatitis (Cohort I), while the other center is a general urological unit (Cohort II). All patients were divided into 3 groups on the basis of the assembled data: patients with symptoms related to prostatitis only (Group I), patients with symptoms related to both prostatitis and BPH (Group II), patients with symptoms related to BPH only (Group III). The rates of positive microbiological results in each group were compared. RESULTS: In the whole period, 9347 patients were analyzed and categorized as follows: Group I, 1884; Group II, 5151; Group III, 2312. Three-thousand and eight-hundred twenty-three patients showed positive culture results (40.9%). The most common isolated species was Escherichia coli (49.7%), followed by Enteroccus spp. (31.8%). The rates of positive M&S tests in the different symptom groups were: Group I, 1532 (81.4%); Group II, 1494 (29.0%); Group III, 797 (34.4%). The overall rate of positive M&S tests in each urology center showed that the center with a staff member who is dedicated to prostatitis studies (Cohort I) had a significantly higher rate of positive M&S tests than the general urological department (Cohort II) (64.3% vs 31.4%; p < 0.001). CONCLUSIONS: Symptom-based patient selection and dedicated staff members will increase the diagnostic yield of the M&S test and reduce the number of unnecessary tests.


Asunto(s)
Selección de Paciente , Prostatitis , Humanos , Masculino , Estudios Retrospectivos , Prostatitis/diagnóstico , Prostatitis/microbiología , Persona de Mediana Edad , Anciano , Hiperplasia Prostática/diagnóstico , Hiperplasia Prostática/complicaciones , Adulto
6.
Int J Urol ; 31(5): 459-463, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38239011

RESUMEN

Prostatitis is a major urological disease affecting 25%-50% of men over their lifetime. However, prostatitis is often overlooked in nonurologic departments due to its sometimes indeterminate symptoms. In this review, we describe how to recognize and treat acute bacterial prostatitis, which manifests as a clinical problem in other departments as well as urology, to help prevent this disease from being overlooked. There are several possible negative effects of not recognizing acute bacterial prostatitis (ABP). First, initial treatment can fail. In the hyperacute phase, common antibiotics are often effective, but in rare cases, such antibiotics may not be effective. In addition, once ABP progresses to form a prostate abscess, potentially avoidable surgical interventions are often needed. A second issue is the transition to chronic prostatitis. If chronic bacterial prostatitis progresses, treatment requires long-term antibiotic administration and the response rate is not high. Some patients may have to deal with urinary tract infections for the rest of their lives. Finally, there is the problem of overlooking the underlying disease. ABP is rare in healthy adult men without underlying disease, including sexually transmitted diseases as well as benign prostatic hyperplasia, urinary stones, and malignant tumors, and may not be obvious. When examining patients with fever of unknown origin, it is necessary to exclude not only infectious diseases but also collagen diseases and malignant tumors. If there are any doubts, we recommend a rectal exam and consultation with a urologist.


Asunto(s)
Antibacterianos , Prostatitis , Humanos , Masculino , Prostatitis/complicaciones , Prostatitis/microbiología , Prostatitis/diagnóstico , Enfermedad Aguda , Antibacterianos/uso terapéutico , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/complicaciones , Enfermedad Crónica
8.
Rev. esp. quimioter ; 36(2): 144-151, abr. 2023. ilus, tab
Artículo en Español | IBECS | ID: ibc-217395

RESUMEN

Objectives: The importance of Gram-positive microorganisms and atypical bacteria in chronic bacterial prostatitis (CBP) has recently been described. For this reason, this study analyzes the etiology of CBP, as well as the evolution of antibiotic resistance through a systematic review. Material and methods: A systematic review of studies obtained through the MEDLINE (PubMed) database, related to the etiology and antibiotic resistance profile of CBP, published up July 1, 2021. Results: The most frequent isolated microorganisms that we have found in publications are Enterococcus faecalis (46.90%), Staphylococcus spp. (22.30%), Escherichia coli (15.09%) and atypical bacteria (6.04%). Conclusions: CBP is undergoing and unprecedented change of paradigm. Gram-positive bacteria and atypical bacteria are the main pathogens involved in the aetiology of this entity. This forces us to rethink the therapeutic strategy used, since it is necessary to use antibiotics that assume the etiological change and the profile of antibiotic resistance described. (AU)


Objetivos: Recientemente se ha descrito la importancia de los microorganismos grampositivos y de las bacterias atípicas en la prostatitis crónica bacteriana (PCB). Por ello, en este estudio se analiza la etiología de la PCB, así como la evolución de la resistencia antibiótica a través de una revisión sistemática. Material y métodos: Se ha realizado una revisión sistemática de estudios obtenidos a través de la base de datos MEDLINE (PubMed), relacionados con la etiología y el perfil de resistencia antibiótica de la PCB, publicados con anterioridad al 1 de julio de 2021. Resultados: Los principales microorganismos aislados en los estudios incluidos en la revisión fueron Enterococcus faecalis (46,90%), Staphylococcus spp. (22,30%), Escherichia coli (15,09%) y bacterias atípicas (6,04%). Conclusiones: La PCB está experimentando un cambio de paradigma, ya que las bacterias grampositivas y las atípicas se erigen como los principales agentes causales de esta entidad. Esto obliga a replantear la estrategia terapéutica utilizada, pues es necesario utilizar antibióticos que asuman el viraje etiológico y el perfil de resistencias antibióticas descrito. (AU)


Asunto(s)
Humanos , Prostatitis/etiología , Prostatitis/microbiología , Farmacorresistencia Microbiana , Bacterias Grampositivas
9.
Rev Esp Quimioter ; 36(3): 275-281, 2023 Jun.
Artículo en Español | MEDLINE | ID: mdl-36869611

RESUMEN

OBJECTIVE: Chronic bacterial prostatitis (CBP) is an entity of difficult clinical diagnosis and treatment, being the microbiological study of semen the main diagnostic test. This study aimed to determine the etiology and antibiotic resistance in patients with symptomatic bacteriospermia (SBP) in our environment. METHODS: A cross-sectional and retrospective descriptive study has been carried out from a Regional Hospital of the Spanish Southeast. The participants were patients assisted in the consultations of the Hospital with clinic compatible with CBP, between 2016 and 2021. The interventions were collection and analysis of the results derived from the microbiological study of the semen sample. The main determinations were the etiology and rate of antibiotic resistance of BPS episodes are analyzed. RESULTS: The main isolated microorganism is Enterococcus faecalis (34.89%), followed by Ureaplasma spp. (13.74%) and Escherichia coli (10.98%). The rate of antibiotic resistance of E. faecalis to quinolones (11%) is lower than previous studies, while for E. coli it has been higher (35%). The low rate of resistance shown by E. faecalis and E. coli to fosfomycin and nitrofurantoin stands out. CONCLUSIONS: In the SBP, gram-positive and atypical bacteria are established as the main causative agents of this entity. This forces us to rethink the therapeutic strategy used, which will avoid the increase in antibiotic resistance, recurrences, and chronicity of this pathology.


Asunto(s)
Antibacterianos , Prostatitis , Masculino , Humanos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Escherichia coli , Estudios Retrospectivos , Estudios Transversales , España/epidemiología , Prostatitis/tratamiento farmacológico , Prostatitis/epidemiología , Prostatitis/microbiología , Farmacorresistencia Microbiana
10.
Rev Esp Quimioter ; 36(2): 144-151, 2023 Apr.
Artículo en Español | MEDLINE | ID: mdl-36622055

RESUMEN

OBJECTIVE: The importance of Gram-positive microorganisms and atypical bacteria in chronic bacterial prostatitis (CBP) has recently been described. For this reason, this study analyzes the etiology of CBP, as well as the evolution of antibiotic resistance through a systematic review. METHODS: A systematic review of studies obtained through the MEDLINE (PubMed) database, related to the etiology and antibiotic resistance profile of CBP, published up July 1, 2021. RESULTS: The most frequent isolated microorganisms that we have found in publications are Enterococcus faecalis (46.90%), Staphylococcus spp. (22.30%), Escherichia coli (15.09%) and atypical bacteria (6.04%). CONCLUSIONS: CBP is undergoing and unprecedented change of paradigm. Gram-positive bacteria and atypical bacteria are the main pathogens involved in the aetiology of this entity. This forces us to rethink the therapeutic strategy used, since it is necessary to use antibiotics that assume the etiological change and the profile of antibiotic resistance described.


Asunto(s)
Infecciones Bacterianas , Prostatitis , Masculino , Humanos , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Infecciones Bacterianas/tratamiento farmacológico , Bacterias , Antibacterianos/uso terapéutico , Bacterias Grampositivas , Escherichia coli , Enfermedad Crónica
11.
Clin Microbiol Infect ; 29(1): 32-37, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-35709903

RESUMEN

BACKGROUND: Bacterial prostatitis is a highly prevalent infection responsible for significant morbidity among men. The diagnosis and treatment for bacterial prostatitis remains complicated. The difficulty in diagnosis is in part owing to the paucity of high-quality evidence that guides a clinician's interpretation of patients' history, physical examination, and laboratory findings. Treatment is challenging because of the few antimicrobials capable of prostate penetration, growing antimicrobial resistance limiting effective treatment options, and the high risk of recurrence. OBJECTIVES: We aimed to provide a useful resource for clinicians in effectively diagnosing and managing acute bacterial prostatitis (ABP) and chronic bacterial prostatitis (CBP). SOURCES: A PubMed literature search on prostatitis was performed with no restrictions on publication date. CONTENT: The epidemiology, pathophysiology, diagnosis, and treatment for ABP and CBP are explored using a clinical vignette as relevant context. IMPLICATIONS: Bacterial prostatitis can be diagnosed through a focused history and microbiological investigations. The Meares-Stamey 4-glass test or modified 2-glass test can help confirm the diagnosis if uncertainty exists. Typical uropathogens are common contributors to bacterial prostatitis but there is growing interest in exploring the role atypical and traditional non-pathogenic organisms may have. Fluoroquinolones remain first-line therapy, followed by trimethoprim-sulfamethoxazole (TMP-SMX) or doxycycline if the pathogen is susceptible. Fosfomycin has emerged as a repurposed and useful agent because of the increasing incidence of multidrug-resistant pathogens. Selection of appropriate antimicrobial regimens can be challenging and is dependent on the host, chronicity of symptoms, uropathogens' susceptibilities, antimicrobials' side effect profile, and the presence of prostatic abscesses or calcifications. ABP can typically be treated similar to other complicated urinary tract infections. However, CBP requires prolonged therapy, with a minimum of 4 weeks and up to 12 weeks of therapy.


Asunto(s)
Antiinfecciosos , Infecciones Bacterianas , Prostatitis , Masculino , Humanos , Prostatitis/diagnóstico , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Antibacterianos/uso terapéutico , Enfermedad Crónica , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/microbiología , Antiinfecciosos/uso terapéutico
12.
Expert Opin Pharmacother ; 23(9): 1091-1101, 2022 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-35574695

RESUMEN

INTRODUCTION: Bacterial prostatitis, acute or chronic, is one of the most prevalent urogenital infections in men. Its diagnosis requires the application of a careful methodology. Gram-negative bacilli are the most frequent causative agents, and in recent years, an increase in the frequency of multiresistant bacteria has been detected. The choice of the optimal antimicrobial treatment requires the selection of drugs with proven in vitro activity associated with good penetration into the prostatic tissue, especially in chronic forms of infection. AREAS COVERED: The aim of this article is to summarize the current evidence regarding the pathogenesis, etiology, empirical and definitive antimicrobial therapy, and new pharmacotherapeutic interventions to improve the prognosis of bacterial acute or chronic prostatitis. EXPERT OPINION: Bacterial prostatitis requires the application of an accurate diagnostic protocol to identify the causative agent and establish the optimal antimicrobial treatment. The structural and biochemical characteristics of prostatic tissue result in poor penetration of antimicrobials; therefore, in the choice of treatment, it is essential to select agents with proven antimicrobial activity and pharmacokinetic characteristics that ensure good and sustained concentrations in this area. Patients with chronic forms of infection require prolonged treatment, and relapses of the infectious process are frequent.


Asunto(s)
Antiinfecciosos , Infecciones Bacterianas , Infecciones Intraabdominales , Prostatitis , Infecciones Urinarias , Antibacterianos/uso terapéutico , Antiinfecciosos/uso terapéutico , Infecciones Bacterianas/diagnóstico , Infecciones Bacterianas/tratamiento farmacológico , Infecciones Bacterianas/microbiología , Enfermedad Crónica , Humanos , Infecciones Intraabdominales/tratamiento farmacológico , Masculino , Prostatitis/diagnóstico , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Infecciones Urinarias/tratamiento farmacológico
13.
Investig Clin Urol ; 63(3): 325-333, 2022 05.
Artículo en Inglés | MEDLINE | ID: mdl-35437957

RESUMEN

PURPOSE: Because of the insufficient efficacy of the current treatment of chronic bacterial prostatitis (CBP), it is justified to search for a more effective antibiotic therapy (ABT). MATERIALS AND METHODS: This single-centre prospective observational comparative study was conducted in 2012 to 2019 (patients: 60 men with CBP; age: 20-45 y). The clinical examination was performed on admission and at 1, 3, 6, or 12 months. All patients underwent the Meares-Stamey test to obtain expressed prostatic secretion (EPS) and/or post-massage urine (PMU) samples for extended bacteriological examination. The patients were randomly divided into 2 treatment groups (30/30 patients): group I, fluoroquinolones (FQs); group II, a combination of FQs with cephalosporins/macrolides with a treatment duration of 1 month. RESULTS: Patients of both groups had severe symptomatic CBP with an average duration of 4 years. Twenty-three microorganisms (15 aerobes, 9 anaerobes) were identified in PMU. At 3 months follow-up, a positive clinical effect was noted in both groups, which was significant (p<0.05) only in group II concerning NIH-CPSI questionnaire, leukocyturia, prostate volume, maximum urine flow, and decreased pathospermia. At 6 months follow-up, in group II the frequency of Escherichia coli and Enterococcus spp. decreased significantly. In group I aerobes changed only insignificantly from the initial level, but anaerobes increased significantly. In group II the titers of both, aerobes and anaerobes, were significantly lower (p<0.05) at 6 months follow-up as compared to initial values. CONCLUSIONS: ABT targeting all taxa in EPS/PMU is a more effective alternative to standard therapeutic regimens for CBP.


Asunto(s)
Infecciones Bacterianas , Prostatitis , Adulto , Antibacterianos/uso terapéutico , Infecciones Bacterianas/tratamiento farmacológico , Enfermedad Crónica , Escherichia coli , Femenino , Fluoroquinolonas , Humanos , Masculino , Persona de Mediana Edad , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Adulto Joven
14.
Int J Biol Macromol ; 209(Pt B): 1593-1604, 2022 Jun 01.
Artículo en Inglés | MEDLINE | ID: mdl-35398386

RESUMEN

Chronic nonbacterial prostatitis (CNP) is a common urology disease. Our previous research found Poria cocos polysaccharides (PPs) alleviated CNP and suggested the effect was related to gut bacteria. We investigated the crucial bacteria and their metabolites responsible for the anti-CNP effect to discover possible mechanisms. The results showed that after the fermentation of PPs by human fecal microbiota, Parabacteroides, Fusicatenibacter, and Parasutterella were significantly enriched. Haloperidol glucuronide and 7-ketodeoxycholic acid generated by these bacteria could be responsible for the increased expression of Alox15 and Pla2g2f and the reduced expression of Cyp1a1 and Hsd17b7 in colon epithelium. The ratio of dihydrotestosterone to estradiol in serum was regulated, and CNP was alleviated. Our results suggested that Parabacteroides, Fusicatenibacter, and Parasutterella could be the essential bacteria in CNP alleviation and their metabolites of PPs 7-ketodeoxycholic acid and haloperidol glucuronide could be the signal molecules of the "gut-prostate axis".


Asunto(s)
Microbioma Gastrointestinal , Poria , Prostatitis , Wolfiporia , Animales , Bacterias , Carbohidratos de la Dieta/farmacología , Glucurónidos , Haloperidol/farmacología , Humanos , Masculino , Polisacáridos/farmacología , Prostatitis/tratamiento farmacológico , Prostatitis/metabolismo , Prostatitis/microbiología , Ratas
15.
Acta Biomater ; 143: 471-486, 2022 04 15.
Artículo en Inglés | MEDLINE | ID: mdl-35259516

RESUMEN

Chronic bacterial prostatitis (CBP) occurs frequently in the male population and significantly influences quality of life. Antibiotics are the main strategy for managing chronic bacterial prostatitis; however, most antibiotics have low efficacy due to their poor penetration of prostate tissues. To overcome this challenge, we fabricated cefpodoxime proxetil (CPD)-loaded reactive oxygen species (ROS)-responsive nanoparticles (NPs) for targeted treatment of CBP. These NPs were modified with folic acid (FA) and could be effectively internalized by bacteria-infected macrophages and prostatic epithelial cells because of the high expression of folate receptors (FRs) in these cells. In vitro cellular assays demonstrated that the CPD-loaded nanomedicine can obviously reduce proinflammatory cytokine expression in cells since the nanomedicine can efficiently eradicate cellular bacteria. In vivo imaging results verified that FA-modified nanomedicines can penetrate the prostatic epithelium and accumulate in the glandular lumen because FRs overexpression was also observed in the prostate tissues of CBP mice. Animal experiments demonstrated that FA-modified nanomedicine can remarkably relieve pelvic pain in CBP mice and dramatically decrease proinflammatory cytokine expression in prostate tissues via eradication of bacteria and scavenging of ROS. Our results provide a new strategy to deliver antibiotics for targeted therapy of CBP. STATEMENT OF SIGNIFICANCE: To overcome poor penetration of antibiotics in prostatic tissues, we developed an antibiotics-loaded ROS-responsive NPs for targeted treatment of CBP. We demonstrated that both bacteria-infected macrophages and prostatic epithelial cells have FRs overexpression, thus FA-modified NPs can be efficiently internalized by these cells. FA-modified NPs can penetrate the prostatic epithelium and accumulate in the glandular lumen via FRs-mediated endocytosis, and the accumulated NPs can smartly release their payload under high ROS microenvironment. A distinguished therapy outcome was obtained in murine CBP model since CPD-loaded NPs can efficiently eradicate the resident bacteria in prostate tissues and downregulate proinflammatory cytokine expression. Our work provides a practicable strategy to expand the application of antibiotics for management of CBP.


Asunto(s)
Nanopartículas , Prostatitis , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Citocinas , Ácido Fólico , Humanos , Masculino , Ratones , Nanomedicina , Nanopartículas/uso terapéutico , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Calidad de Vida , Especies Reactivas de Oxígeno/metabolismo
16.
Expert Opin Drug Saf ; 21(2): 171-182, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34260337

RESUMEN

INTRODUCTION: Chronic bacterial prostatitis (CBP) is a difficult-to-eradicate infection. Antibacterial therapy with currently licensed agents is hindered due to the increasing emergence of pathogen resistance worldwide and to frequent infection relapse. With limited treatment options, physicians are investigating new agents, which, however, may raise safety concerns. AREAS COVERED: Antibacterial agents currently licensed for CBP were not considered. Available reports about the safety and efficacy of antibacterial agents that have been clinically tested or tentatively used to treat CBP in single cases were evaluated. This review also focused on agents targeting Gram-positive pathogens, whose prevalence as causative agents of CBP is increasing. EXPERT OPINION: (i) Most antibacterial agents considered in this review have been administered off-label in the interest of patients, and their use requires particular caution. (ii) Reports describing the usage of many of the drugs reviewed here are still scant, and readers should be warned of the limited published evidence supporting therapy for CBP with these agents. (iii) As treatment must extend over several weeks, medium-term adverse events may occur and therapy should be individualized, taking into account the dosage and the potential toxicity of each specific antibiotic. Regarding dangerous drug-drug interactions, particular attention should be paid to the risk of ECG-QT-interval elongation.


Asunto(s)
Antibacterianos/administración & dosificación , Infecciones Bacterianas/tratamiento farmacológico , Prostatitis/tratamiento farmacológico , Animales , Antibacterianos/efectos adversos , Infecciones Bacterianas/microbiología , Enfermedad Crónica , Relación Dosis-Respuesta a Droga , Humanos , Masculino , Uso Fuera de lo Indicado , Prostatitis/microbiología
17.
Microbiol Spectr ; 9(2): e0053421, 2021 10 31.
Artículo en Inglés | MEDLINE | ID: mdl-34585972

RESUMEN

The aim of the study was to analyze the risk factors for relapse in patients with acute bacterial prostatitis (ABP), focusing on the impact of different antibiotic regimens. We conducted an observational study of all patients diagnosed with ABP (irritative and/or obstructive urinary symptoms, temperature of >37.8°C, and the presence of bacteriuria in urine culture, in the absence of data suggesting pyelonephritis) from January 2017 to December 2018. The main outcome was relapse. We performed a multivariate analysis to identify the risk factors associated with relapse. A propensity score with inverse weighting was applied to attenuate antibiotic selection bias. We included 410 patients. The mean age was 68 years; 28.8% had diabetes mellitus, and 61.1% benign prostatic hyperplasia. The most common isolated bacteria were Escherichia coli (62.4%) and Klebsiella spp. (10%). The overall resistance rate was 39.5% to quinolones. The mortality rate was 1.2%, and the relapse rate was 6.3%. The only independent risk factor for relapse was inadequate antibiotic therapy (odds ratio [OR] 12.3; 95% confidence interval [95% CI], 3.5 to 43.1). When the antibiotic was modified according to the susceptibility pattern, the rates of relapse were 1.8% in those treated with ciprofloxacin, 3.6% with intravenous beta-lactam, 9.3% with co-trimoxazole, and 9.8% with oral (p.o.) beta-lactam (P = 0.03). Treatment with oral beta-lactam (OR, 5.3; 95% CI, 1.2 to 23.3) and co-trimoxazole (OR, 4.9; 95% CI, 1.1 to 23.2) were associated with a risk of relapse. In this large real-life observational study, a significantly higher relapse rate was observed when antibiotic treatment was inadequate. When the antibiotic was tailored, quinolones and intravenous beta-lactams had a lower relapse rate than co-trimoxazole and oral beta-lactams. IMPORTANCE In the manuscript, we report a large series of acute bacterial prostatitis cases and describe data about the etiology, antibiotic resistance rate, and outcome, specially focused on the risk factors for relapse. We found high rates of resistance to the most frequently used antibiotics and a high relapse rate in patients whose treatment was not adjusted according to their microbiological susceptibility. We did not observe differences, though, in mortality or relapse according to appropriate or inappropriate empirical treatment. What is new in this article is the different relapse rates observed depending upon the definitive adequate antibiotic used. Quinolones and intravenous (i.v.) beta-lactam have lower rates of relapse (1.8% and 3.6%, respectively) compared to co-trimoxazole and oral (p.o.) beta-lactam (3.3% and 9.8%, respectively). Clinicians should carefully choose an adequate antibiotic for definitive ABP treatment depending on the results of microbiological isolation, using quinolones as the first option. Whenever quinolones cannot be administered, i.v. beta-lactams seem to be the second-best option.


Asunto(s)
Antibacterianos/uso terapéutico , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Bacteriuria/tratamiento farmacológico , Bacteriuria/microbiología , Enfermedad Crónica , Farmacorresistencia Bacteriana , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prostatitis/mortalidad , Pielonefritis/tratamiento farmacológico , Pielonefritis/microbiología , Quinolonas , Recurrencia , Factores de Riesgo , Combinación Trimetoprim y Sulfametoxazol , beta-Lactamas
18.
Int J Biol Macromol ; 189: 346-355, 2021 Oct 31.
Artículo en Inglés | MEDLINE | ID: mdl-34428489

RESUMEN

Finasteride is an antiandrogenic drug used for the clinical treatment of chronic nonbacterial prostatitis (CNP). Recently, we reported the anti-CNP activity of Poria cocos polysaccharides (PPs) in a rat model. In this study, we compared the differences between PPs and finasteride in treating CNP, especially their effects on the gut microbiota. Results showed that both PPs and finasteride significantly reduced the prostate weight and prostate index of CNP rats, and improved the histological damages in the inflamed prostate. Moreover, PPs and finasteride inhibited the production of pro-inflammatory cytokines (TNF-α, IL-2 and IL-8) and androgens (dihydrotestosterone and testosterone). By 16S rDNA sequencing, PPs and finasteride were found to reprogram the gut microbiota into distinct profiles. Further analysis presented that PPs but not finasteride recovered CNP-induced changes in the gut microbiota, including Ruminococcaceae NK4A214 group, uncultured bacterium f Ruminococcaceae, Ruminiclostridium 9, Phascolarctobacterium, Coriobacteriaceae UCG-002 and Oribacterium. LDA effect size (LEfSe) analysis revealed that PPs recovered the gut microbiota by targeting Ruminococcaceae NK4A214 group. Our results suggested that PPs alleviated CNP via different mechanisms from finasteride, especially by regulating the gut microbiota, which offers therapeutic target for the treatment of CNP.


Asunto(s)
Finasterida/uso terapéutico , Microbioma Gastrointestinal , Polisacáridos/uso terapéutico , Prostatitis/tratamiento farmacológico , Prostatitis/microbiología , Wolfiporia/química , Andrógenos/metabolismo , Animales , Biomarcadores/metabolismo , Enfermedad Crónica , Citocinas/metabolismo , Finasterida/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Mediadores de Inflamación/metabolismo , Masculino , Tamaño de los Órganos/efectos de los fármacos , Filogenia , Próstata/efectos de los fármacos , Próstata/patología , Ratas Sprague-Dawley
19.
Proc Natl Acad Sci U S A ; 118(32)2021 08 10.
Artículo en Inglés | MEDLINE | ID: mdl-34341114

RESUMEN

Prostate adenocarcinoma is the second most commonly diagnosed cancer in men worldwide, and the initiating factors are unknown. Oncogenic TMPRSS2:ERG (ERG+) gene fusions are facilitated by DNA breaks and occur in up to 50% of prostate cancers. Infection-driven inflammation is implicated in the formation of ERG+ fusions, and we hypothesized that these fusions initiate in early inflammation-associated prostate cancer precursor lesions, such as proliferative inflammatory atrophy (PIA), prior to cancer development. We investigated whether bacterial prostatitis is associated with ERG+ precancerous lesions in unique cases with active bacterial infections at the time of radical prostatectomy. We identified a high frequency of ERG+ non-neoplastic-appearing glands in these cases, including ERG+ PIA transitioning to early invasive cancer. These lesions were positive for ERG protein by immunohistochemistry and ERG messenger RNA by in situ hybridization. We additionally verified TMPRSS2:ERG genomic rearrangements in precursor lesions using tricolor fluorescence in situ hybridization. Identification of rearrangement patterns combined with whole-prostate mapping in three dimensions confirmed multiple (up to eight) distinct ERG+ precancerous lesions in infected cases. We further identified the pathogen-derived genotoxin colibactin as a potential source of DNA breaks in clinical cases as well as cultured prostate cells. Overall, we provide evidence that bacterial infections can initiate driver gene alterations in prostate cancer. In addition, our observations indicate that infection-induced ERG+ fusions are an early alteration in the carcinogenic process and that PIA may serve as a direct precursor to prostate cancer.


Asunto(s)
Infecciones Bacterianas/genética , Neoplasias de la Próstata/genética , Neoplasias de la Próstata/microbiología , Serina Endopeptidasas/genética , Atrofia , Infecciones Bacterianas/complicaciones , Infecciones Bacterianas/patología , Roturas del ADN , Humanos , Masculino , Fusión de Oncogenes , Péptidos/genética , Policétidos , Próstata/microbiología , Próstata/patología , Prostatectomía , Neoplasias de la Próstata/patología , Neoplasias de la Próstata/cirugía , Prostatitis/genética , Prostatitis/microbiología , Prostatitis/patología , Regulador Transcripcional ERG/genética
20.
World J Urol ; 39(12): 4373-4379, 2021 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-34213584

RESUMEN

PURPOSE: To evaluate the efficacy and safety of Escherichia coli Nissle 1917 (EcN) in association with levofloxacin in patients with chronic bacterial prostatitis (CBP). METHODS: Patients with CBP referred to our clinic from September 2017 to July 2019 were enrolled. At baseline, the symptomatology was assessed with the NIH-Chronic Prostatitis Symptom Index (NIH-CPSI), while the Meares-Stamey test was used to diagnose the infection. Patients were randomized (1:1) in two groups (A and B). All subjects underwent oral administration of Levoxacin® 500 mg once daily for 4 weeks. Only the patients in Group B underwent oral administration of EcN® 320 mg, twice daily for 4 weeks and then once daily for 8 weeks. After 3 months, each patient repeated the NIH-CPSI questionnaire, while the Meares-Stamey test was repeated at 3 and 6 months in patients who reported persistent symptoms. All adverse events (AEs) were recorded. RESULTS: A total of 110 patients were enrolled. After 3 months patients in Group B reported a significantly lower NIH-CPSI score (5.85 ± 3.07 vs. 7.64 ± 3.86; p = 0.009) and biological recurrences rate (9.8 vs. 26.9%; p = 0.043). At 6 months the biological recurrences rate was significantly lower in Group B (8.7 vs. 28.9%; p = 0.038). Only three patients in Group A and six in Group B (p = 0.25) complained mild AEs. CONCLUSIONS: Combination therapy with EcN and levofloxacin allows a better control of symptoms and biological recurrences in patients with CBP, without worsening the safety of the treatment.


Asunto(s)
Antibacterianos/uso terapéutico , Infecciones Bacterianas/terapia , Escherichia coli , Levofloxacino/uso terapéutico , Prostatitis/microbiología , Prostatitis/terapia , Adolescente , Adulto , Enfermedad Crónica , Terapia Combinada , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...